Influence of tumour micro-environment heterogeneity on therapeutic response (Q29617534)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

1 reference

Junttila MR

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

de Sauvage FJ

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

19 September 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

volume

501

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

page(s)

346-54

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

issue

7467

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

Stromal gene expression predicts clinical outcome in breast cancer

30 April 2017

cites work

1 reference

12 December 2020

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

12 December 2020

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

1 reference

12 December 2020

Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.

1 reference

12 December 2020

A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

1 reference

12 December 2020

Distinct epigenetic changes in the stromal cells of breast cancers

1 reference

12 December 2020

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment

1 reference

12 December 2020

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

12 December 2020

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

1 reference

12 December 2020

A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy

1 reference

12 December 2020

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

12 December 2020

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

1 reference

12 December 2020

Environment-mediated drug resistance: a major contributor to minimal residual disease

1 reference

12 December 2020

CD20+ B cells: the other tumor-infiltrating lymphocytes

1 reference

12 December 2020

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

12 December 2020

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

12 December 2020

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Translational Research Working Group developmental pathway for immune response modifiers.

1 reference

12 December 2020

The humoral immune system has a key prognostic impact in node-negative breast cancer

1 reference

12 December 2020

Immunological aspects of cancer chemotherapy

1 reference

12 December 2020

Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.

1 reference

12 December 2020

Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells

1 reference

12 December 2020

Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

1 reference

12 December 2020

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

1 reference

12 December 2020

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

1 reference

12 December 2020

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

12 December 2020

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

12 December 2020

Anatomic demarcation by positional variation in fibroblast gene expression programs

1 reference

12 December 2020

Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells

1 reference

12 December 2020

Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

1 reference

12 December 2020

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

1 reference

12 December 2020

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

1 reference

12 December 2020

Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.

1 reference

12 December 2020

Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

1 reference

12 December 2020

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

1 reference

12 December 2020

Loss of heterozygosity in normal tissue adjacent to breast carcinomas.

1 reference

12 December 2020

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

12 December 2020

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

1 reference

12 December 2020

Tumors as organs: complex tissues that interface with the entire organism

1 reference

12 December 2020

Basement membranes: structure, assembly and role in tumour angiogenesis

1 reference

12 December 2020

Markers of response for the antiangiogenic agent bevacizumab

1 reference

12 December 2020

Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging

1 reference

12 December 2020

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

1 reference

12 December 2020

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

12 December 2020

Coordinated regulation of myeloid cells by tumours

1 reference

12 December 2020

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

1 reference

12 December 2020

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

1 reference

12 December 2020

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

12 December 2020

Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy.

1 reference

12 December 2020

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

1 reference

12 December 2020

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer

1 reference

12 December 2020

alpha-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma

1 reference

12 December 2020

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

1 reference

12 December 2020

Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

1 reference

12 December 2020

Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells

1 reference

12 December 2020

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

12 December 2020

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

12 December 2020

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

12 December 2020

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

1 reference

12 December 2020

Vascular-bed--specific hemostasis and hypercoagulable states

1 reference

12 December 2020

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

1 reference

12 December 2020

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

12 December 2020

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

1 reference

12 December 2020

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

1 reference

12 December 2020

A perivascular niche for brain tumor stem cells

1 reference

12 December 2020

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

1 reference

12 December 2020

Paracrine Hedgehog signaling in cancer

1 reference

12 December 2020

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

12 December 2020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

12 December 2020

Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells

1 reference

12 December 2020

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

1 reference

12 December 2020

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

1 reference

12 December 2020

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

12 December 2020

Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

Drug resistance and the solid tumor microenvironment

1 reference

12 December 2020

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1 reference

12 December 2020

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

1 reference

12 December 2020

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

12 December 2020

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

1 reference

12 December 2020

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

1 reference

12 December 2020

Cancer immunotherapy comes of age

1 reference

12 December 2020

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

1 reference

12 December 2020

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

1 reference

12 December 2020

Breast-Cancer Stromal Cells withTP53Mutations and Nodal Metastases

1 reference

12 December 2020

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

12 December 2020

The immune contexture in human tumours: impact on clinical outcome

1 reference

12 December 2020

Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome.

1 reference

12 December 2020

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

1 reference

12 December 2020

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer

1 reference

12 December 2020

Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin On

1 reference

12 December 2020

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

1 reference

12 December 2020

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

1 reference

12 December 2020

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

1 reference

12 December 2020

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

1 reference

12 December 2020

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

12 December 2020

Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis

1 reference

12 December 2020

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

Angiogenesis as a therapeutic target

1 reference

12 December 2020

Accessories to the crime: functions of cells recruited to the tumor microenvironment

1 reference

12 December 2020

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE12626

7 January 2021

inferred from DOI database lookup

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE12626

7 January 2021

inferred from DOI database lookup

DNA damage-mediated induction of a chemoresistant niche

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE12626

7 January 2021

inferred from DOI database lookup

Identifiers

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

633700

1051222405

0 references

633700

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=24048067

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017